Results 71 to 80 of about 4,732,777 (361)

Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma

Current Treatment Options in Oncology, 2021
Recently introduced systemic therapies for locally advanced and metastatic non-melanoma skin cancers (NMSCs) are paving the way for neoadjuvant approach.
E. Zelin, I. Zalaudek, M. Agozzino, C. Dianzani, A. Dri, N. di Meo, R. Giuffrida, G. Marangi, N. Neagu, P. Persichetti, L. Toffoli, C. Conforti   +11 more
semanticscholar   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Study on pathological factors affecting the sensitivity of neoadjuvant therapy in hypopharyngeal cancer

Cancer Immunology, Immunotherapy
Objective Hypopharyngeal squamous cell carcinoma (HSCC) is a highly malignant tumor type in the head and neck region. In recent years, neoadjuvant therapy has significantly improved the laryngeal preservation rate among patients.
Gaofei Yin, Nuan Li, Xiaohong Chen, Yang Zhang, Zhigang Huang, Wei Guo   +5 more
doaj   +1 more source

Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors

Translational Oncology
Neoadjuvant therapy is widely used for treating malignant tumors, but its efficacy varies among patients. Currently, tools or biomarkers for early and accurate evaluation of the efficacy of neoadjuvant therapy are lacking.
Jiayi Wang, Jiahui Dai, Yangxi Cheng, Xirui Wang, Rui Deng, Huiyong Zhu   +5 more
doaj   +1 more source

Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer

Zhongliu Fangzhi Yanjiu, 2022
Borderline resectable pancreatic ductal adenocarcinoma accounts for approximately 20% of newly diagnosed pancreatic cancer patients. This type of adenocarcinoma is between resectable and unresectable. It has a high degree of heterogeneity and features in
CHEN Zegang, WANG Yongbing, OU Tao
doaj   +1 more source

Neoadjuvant Therapy [PDF]

Advances in Surgery, 2020
Kristin N. Kelly, Francisco I. Macedo, Nipun B. Merchant   +2 more
openaire   +2 more sources

Neoadjuvant therapy for oesophagogastric cancer

British Journal of Surgery, 2004
Abstract Background The prognosis after surgery for oesophagogastric cancer remains poor. Methods This review clarifies current indications for neoadjuvant therapy for oesophageal and gastric cancer.
F, Lordick, H J, Stein, C, Peschel, J R, Siewert   +3 more
openaire   +2 more sources

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy

Chronic Diseases and Translational Medicine, 2016
Neoadjuvant therapy has become the standard of care for locally advanced mid-low rectal cancer. Pathological complete response (pCR) can be achieved in 12%–38% of patients. Patients with pCR have the most favorable long-term outcomes.
Jian Cui, Hui Fang, Lin Zhang, Yun-Long Wu, Hai-Zeng Zhang   +4 more
doaj   +1 more source

Neoadjuvant therapy for breast cancer [PDF]

Tumori Journal, 2019
Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. Methods: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of ...
Lucia Mangone, Pamela Mancuso, Giovanna Tagliabue, Rosa Angela Filiberti, Giuliano Carrozzi, Silvia Iacovacci, Walter Mazzucco, Rosario Tumino, Pamela Minicozzi, Milena Sant, Paolo Giorgi Rossi   +10 more
openaire   +2 more sources